Agios Pharmaceuticals Inc (NASDAQ:AGIO) Sellers Strengthened Their Shorts By 7.08%

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Corporate Logo

During Q3 2018 the big money sentiment decreased to 1.09. That’s change of 0.39, from 2018Q2’s 1.48. 22 investors sold all, 54 reduced holdings as Agios Pharmaceuticals, Inc. ratio turned negative. 57 increased positions while 26 funds took positions. Funds hold 52.38 million shares thus 0.04% more from 2018Q2’s 52.36 million shares.
Fernwood Inv Mngmt Ltd Liability Corp holds 25,150 shs or 1.03% of its capital. Artal Grp Sa stated it has 300,000 shs. Opus Point Prtnrs Ltd Liability invested in 15,102 shs. Cap Intll Sarl reported 34,400 shs or 0.25% of all its holdings. Teachers Retirement Systems Of The State Of Kentucky reported 49,054 shs or 0.05% of all its holdings. Parallax Volatility Advisers Ltd Partnership, California-based fund reported 1,978 shs. Great West Life Assurance Company Can has invested 0% of its capital in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Amalgamated Retail Bank, a New York-based fund reported 7,117 shs. The United Kingdom-based Polar Capital Llp has invested 0.4% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). S&Co has invested 0.03% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Eventide Asset Limited Liability Com holds 0.21% or 75,000 shs in its capital. Stratos Wealth Prns holds 0% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) or 200 shs. Employees Retirement Association Of Colorado reported 0% stake. Millennium Mgmt Ltd invested in 0.01% or 55,409 shs. Cannell Peter B And Com Incorporated owns 48,485 shs for 0.13% of their capital.

Agios Pharmaceuticals, Inc. had 8 insider sales and 0 insider purchases since July 25, 2018. This’s net activity of $3.18 million. On Friday, August 24 Hoerter Steven L. had sold 2,050 shs worth $153,586. $249,215 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) was sold by Biller Scott. $2.00 million worth of stock was sold by MARAGANORE JOHN on Tuesday, September 11. The insider Bowden Christopher sold 2,000 shs worth $160,051.

Agios Pharmaceuticals Inc (NASDAQ:AGIO) had an increase of its shorted shares by 7.08%. It was published in January by FINRA the 6.90 million shorted shares on AGIO. The up change of 7.08% from 6.44M shares was reported. With Average volume 508,100, AGIO’s former position will take 14 days to recover.

AGIO is reaching $54.64 during the last trading session, after decreased 1.53%.Agios Pharmaceuticals, Inc. has 670,255 shares volume, 8.25% up from normal. AGIO is downtrending and has moved 13.33% since January 12, 2018. AGIO underperformed by 13.33% the S&P 500.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States.The firm is valued at $3.18 billion. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML.Last it reported negative earnings. The firm is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients.

For more Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) news published briefly go to: Nasdaq.com, Seekingalpha.com, Nasdaq.com, Globenewswire.com or Seekingalpha.com. The titles are as follows: “Agios Out-Licenses China Rights to Leukemia Drug Tibsovo – Nasdaq” published on June 27, 2018, “Premarket analyst action – healthcare – Seeking Alpha” on September 25, 2018, “Agios Pharmaceuticals Becomes Oversold (AGIO) – Nasdaq” with a publish date: August 08, 2018, “Agios Reports Second Quarter 2018 Financial Results Nasdaq:AGIO – GlobeNewswire” and the last “Questioning Agios Pharmaceuticals’ Future Revenue – Seeking Alpha” with publication date: December 07, 2018.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.